OtherClinical Investigations (Human)
First-in-Human Phase I study of CTT1057, a Novel 18F Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate Specific Membrane Antigen in Prostate Cancer
Spencer C Behr, Rahul Aggarwal, Henry F. Van Brocklin, Robert R Flavell, Kenneth Geo, Eric J. Small, Joseph Blecha, Salma Jivan, Thomas A. Hope, Jeffrey P. Simko, John Kurhanewicz, Susan M. Noworolski, Natalie J. Korn, Romelyn De Los Santos, Matthew R. Cooperberg, Peter R Carroll, Hao G. Nguyen, Kirsten L. Greene, Beatrice Langton-Webster, Clifford E Berkman and Youngho Seo
Journal of Nuclear Medicine November 2018, jnumed.118.220715; DOI: https://doi.org/10.2967/jnumed.118.220715
Spencer C Behr
1 University of California, San Francisco, United States;
Rahul Aggarwal
1 University of California, San Francisco, United States;
Henry F. Van Brocklin
2 University of California San Francisco, United States;
Robert R Flavell
1 University of California, San Francisco, United States;
Kenneth Geo
1 University of California, San Francisco, United States;
Eric J. Small
1 University of California, San Francisco, United States;
Joseph Blecha
1 University of California, San Francisco, United States;
Salma Jivan
1 University of California, San Francisco, United States;
Thomas A. Hope
1 University of California, San Francisco, United States;
Jeffrey P. Simko
1 University of California, San Francisco, United States;
John Kurhanewicz
1 University of California, San Francisco, United States;
Susan M. Noworolski
1 University of California, San Francisco, United States;
Natalie J. Korn
1 University of California, San Francisco, United States;
Romelyn De Los Santos
1 University of California, San Francisco, United States;
Matthew R. Cooperberg
1 University of California, San Francisco, United States;
Peter R Carroll
1 University of California, San Francisco, United States;
Hao G. Nguyen
1 University of California, San Francisco, United States;
Kirsten L. Greene
1 University of California, San Francisco, United States;
Beatrice Langton-Webster
3 Cancer Targeted Technology;
Clifford E Berkman
4 Washington State Univ, United States
Youngho Seo
1 University of California, San Francisco, United States;
Article Figures & Data
Additional Files
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 65, Issue 3
March 1, 2024
First-in-Human Phase I study of CTT1057, a Novel 18F Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate Specific Membrane Antigen in Prostate Cancer
Spencer C Behr, Rahul Aggarwal, Henry F. Van Brocklin, Robert R Flavell, Kenneth Geo, Eric J. Small, Joseph Blecha, Salma Jivan, Thomas A. Hope, Jeffrey P. Simko, John Kurhanewicz, Susan M. Noworolski, Natalie J. Korn, Romelyn De Los Santos, Matthew R. Cooperberg, Peter R Carroll, Hao G. Nguyen, Kirsten L. Greene, Beatrice Langton-Webster, Clifford E Berkman, Youngho Seo
Journal of Nuclear Medicine Nov 2018, jnumed.118.220715; DOI: 10.2967/jnumed.118.220715
First-in-Human Phase I study of CTT1057, a Novel 18F Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate Specific Membrane Antigen in Prostate Cancer
Spencer C Behr, Rahul Aggarwal, Henry F. Van Brocklin, Robert R Flavell, Kenneth Geo, Eric J. Small, Joseph Blecha, Salma Jivan, Thomas A. Hope, Jeffrey P. Simko, John Kurhanewicz, Susan M. Noworolski, Natalie J. Korn, Romelyn De Los Santos, Matthew R. Cooperberg, Peter R Carroll, Hao G. Nguyen, Kirsten L. Greene, Beatrice Langton-Webster, Clifford E Berkman, Youngho Seo
Journal of Nuclear Medicine Nov 2018, jnumed.118.220715; DOI: 10.2967/jnumed.118.220715
Jump to section
Related Articles
Cited By...
- No citing articles found.